Becton Dickinson trades at a forward P/E of roughly 13x—a 3550% discount to medtech peers—despite owning 60% of the U.S. infusion pump market, generating over 90% of revenue from recurring consumables, and posting a record 25% adjusted operating margin in FY2025.
The disconnect stems from a FY2026 transition year narrative after BD completed the spin-off of its Biosciences and Diagnostic Solutions business to Waters Corporation on February 9, 2026. But beneath the noise, a leaner, faster-growing pure-play MedTech company is emerging, one with multiple billion-dollar growth platforms, an accelerating margin trajectory, and $4 billion in fresh capital to deploy.
The single metric that best captures BD's transformation is adjusted operating margin expansion. This KPI synthesizes everything working in BD's favor: BD Excellence operational improvements, portfolio simplification, pricing discipline, and mix shift toward higher-margin connected care and biologics delivery into one number that flows directly to earnings power.
Adjusted operating margin expanded roughly 80 basis points per year from FY2023 through FY2025, reaching a record 25.0%. Management is guiding to hold the 25% margin floor in FY2026 despite a roughly 370 basis point tariff headwind on adjusted EPS. BD Excellence productivity gains, running at 8% in Q1 FY2026, are fully offsetting tariffs on the margin line.
The company has reduced its manufacturing footprint from over 90 global sites to fewer than 50, launched a $200 million cost-out program (75% already in execution), and is shortening product development timelines by 6–12 months. When tariffs normalize, the underlying margin trajectory points to 26%+ territory.
BD's Q1 FY2026 (October–December 2025) marked the first quarter of the post-spin era. Total revenue reached $5.25 billion, up 1.6% as reported. The New BD perimeter generated $4.49 billion, growing 3.5% reported and 2.5% on a currency-neutral basis. Adjusted EPS of $2.91 declined 15.2% year-over-year—a number distorted by tariff impacts and the structural change from the Waters separation.
Connected Care grew 5.5%, driven by Alaris competitive wins, pharmacy automation growing at double digits, and the Advanced Patient Monitoring business (acquired from Edwards Lifesciences for $4.2B) delivering high-single-digit growth. BD Interventional posted $1.33 billion in revenue, up 5.8%, with PureWick achieving double-digit growth. BioPharma Systems grew 2.7%, with biologics delivery—led by GLP-1 drugs—recording double-digit growth.
Full-year FY2025 delivered $21.8 billion in revenue (+8.2% reported), $14.40 in adjusted EPS (+9.6%), and $2.7 billion in free cash flow. For FY2026, management guided New BD adjusted EPS to $12.35–$12.65, representing approximately 6% growth at midpoint excluding the $275 million tariff headwind.
Perhaps the most underappreciated growth driver is BD's drug delivery platform. Over 80 novel and biosimilar GLP-1 molecules are now contracted on BD prefillable syringes and autoinjectors, up from roughly 40 in mid-2024. BD has invested $110 million in a Nebraska manufacturing expansion to meet surging demand.
Management's target of $1 billion in annual drug delivery revenue by 2030 represents roughly 5x current levels. This is a high-margin, razor-and-blade business: once a pharma company qualifies its drug on a BD device, switching costs are enormous due to regulatory re-filing requirements. The GLP-1 wave provides a durable, secular demand tailwind independent of hospital capital spending cycles.
The bullish thesis rests on five concrete business drivers, each with quantifiable P&L impact.